Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 12/20 | 0.48 |
| ▸ | CES1 | P23141 | 11/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | XBP1 | P17861 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10476789 | 0.84 | CES2 (0.67) | CES2CES1MAPTLMNANPSR1 | |
| SCHEMBL761381 | 0.82 | CES2 (0.65) | CES2CES1MAPTLMNANPSR1 | |
| SCHEMBL29352153 | 0.79 | ALDH1A1 (0.61) | CES2CES1MAPTLMNASMN1; SMN2 | |
| SCHEMBL11682716 | 0.77 | CES2 (0.72) | CES2CES1MAPTLMNANPSR1 | |
| SCHEMBL29147820 | 0.77 | CES2 (0.56) | CES2CES1MAPTLMNANPSR1 | |
| SCHEMBL31478261 | 0.76 | CES2 (0.58) | CES2CES1MAPTLMNANPSR1 | |
| SCHEMBL28735064 | 0.76 | CES2 (0.73) | CES2CES1MAPTLMNANPSR1 | |
| SCHEMBL28735145 | 0.76 | CES2 (0.58) | CES2CES1MAPTLMNANPSR1 | |
| SCHEMBL198842 | 0.76 | CES2 (0.73) | CES2CES1MAPTLMNANPSR1 | |
| SCHEMBL28735070 | 0.76 | CES2 (0.73) | CES2CES1MAPTLMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150157605-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | JENRIN DISCOVERY, INC. | 2015-06-11 | — | — | US | disclosed |
| US-8853252-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes | JENRIN DISCOVERY, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8648072-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes | JENRIN DISCOVERY, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-8580768-B2 | Cannabinoid receptor antagonists-inverse agonists useful for treating metabolic disorders, including obesity and diabetes | JENRIN DISCOVERY, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130005784-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | JENRIN DISCOVERY (US) | 2013-01-03 | — | — | US | disclosed |
| US-20120264754-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | JENRIN DISCOVERY (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120264797-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | JENRIN DISCOVERY (US) | 2012-10-18 | — | — | US | disclosed |
| US-8217038-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes | JENRIN DISCOVERY, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-20120157414-A1 | CANNABINOID RECEPTOR ANTAGONISTS-INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | JENRIN DISCOVERY (US) | 2012-06-21 | — | — | US | disclosed |
| US-8138216-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes | JENRIN DISCOVERY, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8088809-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes | JENRIN DISCOVERY, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20110257178-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | JENRIN DISCOVERY (US) | 2011-10-20 | — | — | US | disclosed |
| US-20100152260-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | JENRIN DISCOVERY (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100105751-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | JENRIN DISCOVERY (US) | 2010-04-29 | — | — | US | disclosed |
| US-7666889-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes | JENRIN DISCOVERY, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7655685-B2 | Cardiometabolic disorders like obesity, diabetes, hypertension and dyslipidemias, 3, 4-diarylpyrazole derivatives; highly selective; limited or no CNS adverse side effects, including mood disorders | JENRIN DISCOVERY, INC. (US) | 2010-02-02 | — | — | US | disclosed |
| US-20090118345-A1 | Cardiometabolic disorders like obesity, diabetes, hypertension and dyslipidemias, 3, 4-diarylpyrazole derivatives; highly selective; limited or no CNS adverse side effects, including mood disorders | JENRIN DISCOVERY (US) | 2009-05-07 | — | — | US | disclosed |
| US-20090036511-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | JENRIN DISCOVERY (US) | 2009-02-05 | — | — | US | disclosed |
| US-7482470-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes | JENRIN DISCOVERY, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20070259934-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | JENRIN DISCOVERY (US) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005784-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | CNR2, CNR1, GPR119 | CES2 864/4885CES1 234/4885MAPT 4129/4885 |
| US-20090118345-A1 | Cardiometabolic disorders like obesity, diabetes, hypertension and dyslipidemias, 3, 4-diarylpyrazole derivatives; highly selective; limited or no CNS adverse side effects, including mood disorders | CNR2, CNR1, GPR119 | CES2 329/4885CES1 18/4885MAPT 2483/4885 |
| US-20120264754-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | CNR2, CNR1, GPR119 | CES2 1221/4885CES1 157/4885MAPT 4195/4885 |
| US-20070259934-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | CNR2, CNR1, GPR119 | CES2 864/4885CES1 234/4885MAPT 4129/4885 |
| US-20100105751-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | CNR2, CNR1, GPR119 | CES2 667/4885CES1 91/4885MAPT 4019/4885 |
| US-20120264797-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | CNR2, CNR1, GPR119 | CES2 667/4885CES1 91/4885MAPT 4019/4885 |
| US-20090036511-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | CNR2, CNR1, GPR119 | CES2 864/4885CES1 234/4885MAPT 4129/4885 |
| US-20120157414-A1 | CANNABINOID RECEPTOR ANTAGONISTS-INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | CNR2, CNR1, GPR119 | CES2 1204/4885CES1 157/4885MAPT 4258/4885 |
| US-20100152260-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | CNR2, CNR1, GPR119 | CES2 864/4885CES1 234/4885MAPT 4129/4885 |
| US-20150157605-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | CNR2, CNR1, GPR119 | CES2 667/4885CES1 91/4885MAPT 4019/4885 |
| US-20110257178-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | CNR2, CNR1, GPR119 | CES2 1221/4885CES1 157/4885MAPT 4195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.